Diagnosis and management of core-binding factor leukemias.
The core-binding factor (CBF) leukemias are the subtype of acute myelogenous leukemia (AML) associated with the highest response to therapy and longest remission duration. Although CBF leukemias have two distinctly different morphologic and clinical presentations (i.e., AML M2 and AML M4eo), their molecular pathophysiology is linked by their abnormalities in different subunits of CBF, a transcription factor important in several pathways in hematopoietic cells. This article summarizes the recent biologic and clinical advances made in the treatment of these diseases.
Seiter
Karen
K
Division of Hematology/Oncology, New York Medical College, Room 250 Munger Pavilion, Valhalla, NY 10595, USA. Karen_Seiter@nymc.edu
D002869:Chromosome Aberrations; D050660:Core Binding Factors; D019468:Disease Management; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D025202:Molecular Diagnostic Techniques; D009363:Neoplasm Proteins; D011379:Prognosis; D014157:Transcription Factors / Q000235:genetics*
D050660:Core Binding Factors; D009363:Neoplasm Proteins; D014157:Transcription Factors